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poorly, if at all [3, 6]. In other cases where ligand binding
is kinetically slow compared to the rate of transcription
(e.g., for the FMN [12] and purine [11] riboswitches),
pausing allows the aptamer domain sufficient time to
bind ligand if the metabolite’s intracellular concentration
is sufficiently high. This binding interaction allows the
RNA to proceed from the F to F* state (Figure 1B). For
the pbuE adenine riboswitch [5], acquisition of the F*
state determines that transcription will be aborted and
thus turns off gene expression.
In the absence of ligand, the 30 side of the P1 helix dis-
sociates from the aptamer domain and is used to form
a stem-loop structure in the expression platform that
dictates the second genetic outcome, upregulation of
transcription (Figure 1B). A second pause site, usually
found in the middle of the expression platform, enables
riboswitches to perform the intrinsically slow second-
ary structural rearrangement (F/ Fz in Figure 1B) that
leads to active transcription of the downstream coding
sequence [12].
Previous studies have noted the necessity for the
loop-loop interaction in ligand recognition, but they were
unable to provide a plausible connecting mechanism.
This coupling is an important issue, as three-way junc-
tions are a ubiquitous structural motif for higher-order
organization of RNA, involved in forming protein binding
and catalytic active sites [13]. Characterization of the
natural (‘‘fast’’) hammerhead ribozyme revealed that a
loop-loop interaction facilitates organization of the cat-
alytic site located in a three-way junction, allowing it
to cleave at greatly accelerated rates in physiologically
relevant magnesium concentrations [14, 15]. Strikingly,
this RNA has strong architectural similarities to the
adenine riboswitch, illustrating that organization of
functional RNA junctions is often facilitated by other
elements of tertiary structure [16]. These recent
studies underscore that we are still just beginning to
understand how the ability of RNA to fold into intricate
three-dimensional structures allows them to execute
their diverse cellular functions.
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MAP Kinase Inhibitors
The current study by Kim et al. [1] (in this issue of
Chemistry & Biology) uses a genetic approach with
the yeast Schizosaccharomyces pombe to identify a
highly specific inhibitor of Spc1 MAP kinase that com-
petes with protein substrates for Spc1 interactions,
but not with ATP binding.
Mitogen activated protein (MAP) kinases are key signal-
ing proteins that mediate cellular responses to extracel-
lular signals. Overactivation of the MAP kinase signalingpathways, primarily through genetic mutations of up-
stream regulatory proteins, is thought to play a prominent
role in inflammatory diseases and tumor cell prolifera-
tion [2]. Thus, there is wide interest in the development
of specific and effective MAP kinase inhibitors. In this is-
sue of Chemistry & Biology [1], Kim et al. describe the
identification of a highly specific, small molecular weight
isoquinolinium compound that appears to inhibit only
a specific MAP kinase isoform found in the yeastSchizo-
saccharomyces pombe (S. pombe) but has little effect
on the activity of other yeast MAP kinases, MAP kinase
activators, or homologous MAP kinases from mamma-
lian species. These findings may help set the stage for
the development of highly specific and hopefully more
clinically effective MAP kinase inhibitors.
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808The identification of the inhibitory isoquinolinium
compound, which the authors termed HWY 5069, uti-
lized a genetic approach involving the yeast S. pombe.
This ‘‘model organism’’ approach, which has also been
exploited in Saccharomyces cerevisiae, Caenorhabditis
elegans, and Drosophila melanogaster [3], involves the
genetic manipulation of proteins to create mutant
strains of S. pombe that contain deletions of specific
signaling proteins found within the various MAP kinase
pathways. Subsequently, the proliferation of the various
mutant strains along with the wild-type S. pombe was
examined in the presence or absence of test com-
pounds; in this study a proprietary collection of 80 iso-
quinolinium derivatives was examined [1]. It is quite in-
teresting that all of the S. pombe deletion mutants are
viable and appear to have similar proliferation rates.
The premise for this model is that inhibition of S. pombe
proliferation will only occur if both the inhibitory test
compound and its target protein are present. In con-
trast, proliferation of the mutant strain lacking the pro-
tein target of the inhibitory test compound would not
be affected by compound treatment. As such, S. pombe
strains with the intact Spc1 MAP kinase protein were
sensitive to HWY 5069, whereas mutant strains lacking
Spc1 were resistant to the test compound, implicating
this MAP kinase as the HWY 5069 target. There is prece-
dent for this type of model. For example, the antimicro-
bial and immunosuppressant compounds rapamycin
and FK506 are ineffective inhibitors of proliferation in
yeast strains that lack the rapamycin and FK506 target
protein FKBP12 [4]. It is the rapamycin or FK506 mole-
cule in complex with FKBP12 that acts as the functional
inhibitor of other proteins involved in inflammation and
cell proliferation. In the current paper [1], the authors pro-
pose a somewhat similar model where HWY 5069 must
first form a complex with Spc1, inducing a conforma-
tional change in the protein that allows the recruitment
of another protein(s) that inhibits Spc1 activity and pre-
vents cell proliferation. Future studies will be needed to
identify any recruited proteins and to establish firmly
whether this model reflects the mechanism of action
for HWY 5069 inhibition of Spc1.
However, Kim et al. have begun to shed some light on
how this molecule works. For example, the authors ad-
dress the question of whether HWY 5069 inhibits Spc1
activity by competing with ATP binding or with substrate
protein interactions. To test this, the authors preincu-
bated purified Spc1 with varying amounts of ATP or my-
elin basic protein (MBP) as Spc1 substrates [1]. Whereas
preincubation with ATP had no affect on HWY 5069 inhi-
bition of Spc1 kinase activity, preincubation with in-
creasing concentrations of MBP reversed HWY 5069’s
ability to inhibit Spc1 activity in vitro. These findings pro-
vide evidence to support the conclusion that HWY 5069
functions in an ATP-independent manner and involves
competition with substrate proteins that are phosphory-
lated by Spc1. This is an important finding, as kinase
inhibitors that compete with ATP binding are notorious
for their nonspecificity due to the generally conserved
nature of ATP binding domains on protein kinases [5].
While MBP is a commonly used MAP kinase substrate
in activity assays, it is also phosphorylated by many
other types of kinases. Thus, it will be interesting to de-
termine whether HWY 5096 can also compete with andprevent the phosphorylation of more physiological
Spc1 substrates such as the transcription factor Atf1 [6].
The authors further demonstrate that HWY 5069 does
not require functionally active Spc1 protein to be effec-
tive. In these experiments, S. pombe cell lines that ex-
pressed either the wild-type or a kinase-inactive mutant
of Spc1 were treated with HWY 5069 [1]. Interestingly,
the proliferation of both cell lines was equally sensitive
to the inhibitory effects of HWY 5069, indicating that
Spc1 activity was irrelevant to the proposed HWY 5069-
induced conformational changes in Spc1. This model will
likely be tested by identifying the domain(s) on Spc1 in-
volved in HWY 5069 interactions. The characterization
of the HWY 5069 binding site on Spc1 will be important
not only for generating appropriate chemical modifica-
tions to improve the efficacy of this compound but also
for the development of novel inhibitors against other
MAP kinases that are relevant in human diseases.
The authors suggest that HWY 5069 interactions with
Spc1 are relatively weak and probably noncovalent. This
was shown by preincubating the Spc1 kinase with in-
creasing concentrations of NaCl in vitro [1]. The premise
of this experiment is that the more avid the interactions
between HWY 5069 and Spc1, the higher the NaCl con-
centration required to disrupt these interactions and to
prevent HWY 5069 from inhibiting Spc1. However, as
the authors show, as little as 40 mM NaCl prevented
HWY 5069 from inhibiting Spc1, indicating weak associ-
ations between the test compound and its putative tar-
get. However, definitive details as to the mechanism of
action for HWY 5069 will require further structural infor-
mation using methods such as X-ray crystallography to
characterize binding interactions of HWY 5069 with
Spc1. Structural analysis is not a trivial undertaking
and will depend upon the ability of HWY 5069 to cocrys-
tallize with Spc1.
Extensive structural information is available for p38a
MAP kinase, which is the closest mammalian homolog
of Spc1 [7]. As a result, several docking domains on
p38a MAP kinase have been shown to facilitate specific
interactions with protein substrates [8]. It will be interest-
ing to see if the 3D structure of these docking domains on
p38a and Spc1 MAP kinases is different given that HWY
5069 has no effect on p38a activity [1]. A structural differ-
ence could explain HWY 5069 specificity, as the p38a
MAP kinase common docking (CD: Asp313, Asp315,
Asp316) and ED (Glu160, Asp161) domains differ by a sin-
gle amino acid in the corresponding regions of Spc1 (CD:
Asp304, Thr306, Asp307; ED: Glu151, Asn152).
The study by Song and coworkers describes a power-
ful genetic-based method for the identification of a spe-
cific inhibitor of a yeast MAP kinase. Because of the high
conservation of MAP kinases from yeast to humans, this
approach may be tested with other chemical libraries
for identifying novel inhibitors of other family members.
While the ultimate utility of HWY 5069 or derivatives of
this molecule for use as clinical agents is yet to be de-
termined, the findings presented suggest that this
compound may show promise for development into an
antifungal agent. To further build on these data, addi-
tional studies incorporating structural and cell biology
techniques will be essential to discern the mode of ac-
tion for HWY 5069. This information will help move for-
ward the development of this molecule and may lead
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809to the discovery of novel inhibitors that are selective
against other MAP kinases involved in human diseases.
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